Takeda Buys into Viral Immunology with US$1 B Turnstone Deal

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 12 (Table of Contents)

Published: 24 Dec-2019

DOI: 10.3833/pdr.v2019.i12.2480     ISSN: 1756-7874

Section: Research & Development



In an effort to build its immuno-oncology franchise, Takeda Pharmaceutical has entered into a strategic collaboration with Turnstone Biologicsto develop products from Turnstone’s proprietary vaccinia virus platform targeting a broad range of cancer indications...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details